GlassScriptPhysician profile
April Elam
NPI 1972869568
$8,244.17
in general payments reported to CMS, 2019-2025
28 companies · $645 in 2025
The $645 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $753 · 2020: $754 · 2021: $1,476 · 2022: $1,910 · 2023: $1,400 · 2024: $1,307 · 2025: $645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,352.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,352.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,181.27 | 2019-2024 | Xarelto |
| Abbvie INC. | $880.69 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $759.83 | 2020-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Novartis Pharmaceuticals Corporation | $692.62 | 2019-2025 | |
| Gilead Sciences, INC. | $685.57 | 2021-2025 | |
| Pfizer INC. | $607.41 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $447.81 | 2019-2024 | Farxiga, Fasenra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $413.32 | 2019-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $380.51 | 2019-2025 | Zerbaxa, Dificid |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $341.67 | 2019-2025 | Lifevest |
| Paratek Pharmaceuticals, INC. | $290.58 | 2019-2024 | Nuzyra |
| Boston Scientific Corporation | $244.40 | 2019-2025 | Watchman Flx, Watchman, Watchman Access System |
| Alnylam Pharmaceuticals INC. | $201.01 | 2022-2024 | Givlaari |
| Philips North America LLC | $183.73 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $182.98 | 2019-2024 | Eliquis, Camzyos |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $170.09 | 2021-2025 | Ultomiris |
| Melinta Therapeutics, LLC | $164.85 | 2019-2022 | |
| Electromed, INC. | $119.34 | 2019-2023 | Smartvest |
| Otsuka America Pharmaceutical, INC. | $72.41 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $52.59 | 2020-2021 | |
| Inari Medical, INC. | $36.92 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Scpharmaceuticals INC. | $35.33 | 2024 | |
| Abbott Laboratories | $23.79 | 2024 | Freestyle Libre 3 |
| Bioxcel Therapeutics, INC. | $17.03 | 2023 | Igalmi |
| Masimo Corporation | $15.79 | 2021 | |
| Glaxosmithkline, LLC. | $15.78 | 2025 | Trelegy Ellipta |
| Shire North American Group INC | $14.13 | 2019 | |
| Tactile Systems Technology INC | $12.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Elam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.